CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference

Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) announces its participation in two major investor conferences. The Canaccord Genuity Virtual MedTech Forum will feature CEO Dr. Phillip Chan on November 18, 2021, at 11:00 a.m. ET. A second presentation is scheduled for the Jefferies London Healthcare Conference on the same day, available on-demand starting at 3:00 a.m. ET. An archive of both presentations will be available for 30 days on their website. CytoSorbents specializes in blood purification technologies to treat critical illnesses and is effective in over 70 countries.

MONMOUTH JUNCTION, N.J., Nov. 15, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences.

CytoSorbents will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021. Dr. Phillip Chan, CytoSorbents' Chief Executive Officer, will present a brief overview of the Company operations and outlook at 11:00 a.m. Eastern time accessible via the following Webcast Link. Company management will also meet with investors throughout the day.

Dr. Chan will also present at the 2021 Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing via the following Webcast Link, starting Thursday, November 18, 2021 at 3:00 a.m. Eastern time. Management will also hold investor meetings on Friday, November 19, 2021.

An archived recording of CytoSorbents' presentations at both investor conferences will be available under the Investor Relations portion of the Company's website at Events & Presentations - Cytosorbents, and will be available for 30 days.

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 152,000 cumulative CytoSorb devices have been utilized to date. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is initiating two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR–D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us onFacebook and Twitter. 

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2021, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
tpowers@cytosorbents.com

U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-and-jefferies-london-healthcare-conference-301424592.html

SOURCE CytoSorbents Corporation

FAQ

When will CytoSorbents present at the Canaccord Genuity Virtual MedTech Forum?

CytoSorbents will present at the Canaccord Genuity Virtual MedTech Forum on November 18, 2021, at 11:00 a.m. Eastern time.

Where can I watch CytoSorbents' presentations from the investor conferences?

The presentations will be available for on-demand viewing on CytoSorbents' Investor Relations page starting November 18, 2021, for 30 days.

What is CytoSorbents' main product?

CytoSorbents' flagship product is CytoSorb®, a blood purification technology designed to treat cytokine storms in critical illnesses.

What are the key conferences CytoSorbents is participating in?

CytoSorbents is participating in the Canaccord Genuity Virtual MedTech Forum and the Jefferies London Healthcare Conference.

What is the significance of CytoSorbents' participation in these conferences?

The conferences provide an opportunity for CytoSorbents to present its operations and outlook to potential investors.